Ocugen licenses OCU400 gene therapy to Kwangdong for South Korea; $1M upfront, up to $6.5M milestones

Ocugen, Inc.

Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.
$1M upfront; up to $6.5M in regulatory/development milestones plus sales milestones of $1.5M per $15M sales.
Royalty of 25% on net sales; Ocugen to manufacture commercial supply under separate agreement.
Term continues until 20 years after first commercial sale or last valid patent/exclusivity expiry.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.